Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ondrej Bilek"'
Autor:
Magda Barinova, Bohuslav Melichar, Karolina Hurdalkova, Martin Svaton, Jiri Blazek, Lenka Jakubíková, M. Černovská, Michal Jirousek, Daniel Krejci, Jana Skrickova, Milada Zemanova, J. Krejčí, Petra Zemanova, Michal Hrnčiarik, Ondrej Bilek, Ondrej Fischer, Juraj Kultan
Publikováno v:
Anticancer Research. 40:2209-2217
To investigate potential association between administration of corticosteroids, antibiotics, probiotics, proton pump inhibitors, non-steroidal anti-inflammatory drugs (NSAID), statins and metformin and outcome in patients with non-small cell lung can
Autor:
Jan Jurica, Jiri Vasina, Lenka Zdrazilova-Dubska, Tomas Kazda, Iveta Selingerová, Alexandr Poprach, Simona Borilova, Ondrej Bilek, Miloš Holánek, Sona Stepankova, Igor Kiss
Publikováno v:
International immunopharmacology. 99
ALK targeting with tyrosine kinase inhibitors (TKIs) is a highly potent treatment option for the therapy of ALK positive non-small cell lung cancer (NSCLC). However, pharmacokinetics of TKIs leads to clinically significant drug interactions, and the
Autor:
Iveta Selingerová, Tomas Kazda, Ivana Kolouskova, Katarína Petráková, Miloš Holánek, Oldrich Coufal, Ondrej Bilek, Radka Obermannova, Lenka Foretova, Pavel Fabian, Marek Svoboda, Alexandr Poprach, Mária Zvaríková
Publikováno v:
Cancers
Cancers, Vol 13, Iss 1586, p 1586 (2021)
Volume 13
Issue 7
Cancers, Vol 13, Iss 1586, p 1586 (2021)
Volume 13
Issue 7
Pathological complete response (pCR) achievement is undoubtedly the essential goal of neoadjuvant therapy for breast cancer, directly affecting survival endpoints. This retrospective study of 237 triple-negative breast cancer (TNBC) patients with a m